31 Mar 2023
Assets29.75
Total Income36.42
EBITDA3.28
Profit After Tax1.88
NET Worth1.01
Reserves and Surplus0.51
Total Borrowing16.19
At a glance
Updated 2026-09-10The shares listed at ₹146.10, a 14.14% move from the issue price. Curis Lifesciences is a SME IPO with an issue size of ₹27.52 crore, proposed for listing on NSE SME. The offer opens on 7th Nov 2025 and closes on 11th Nov 2025. The issue structure includes a fresh issue of ₹26.14 crore. The current listing schedule points to 14th Nov 2025.
Issue details
Listing atNSE SME
Issue typeBook Build Issue
Issue size₹27.52 Cr
Fresh issue₹26.14 Cr
Face value₹10
Price band₹120.00–₹128.00
Allotment12th Nov 2025
Listing14th Nov 2025
Listing performance
Full performance ↗Issue price₹128.00
Listing price₹146.10
Current price—
Listing gain14.14%
Current return—
Price progressionIssue → Listing → Current
Grey market
GMP page ↗Latest GMP₹9.00
GMP / upper price7.03%
Est. listing₹137.00
GMP is unofficial sentiment data, not an exchange price.
Timeline
Opens7th Nov 2025
Closes11th Nov 2025
Allotment12th Nov 2025
Refund13th Nov 2025
Demat13th Nov 2025
Listing14th Nov 2025
Subscription demand
Full bidding ↗QIB96.17×
sHNI60.38×
bHNI93.99×
NII / HNI93.99×
Retail44.28×
Total74.39×
Lot size
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Minimum Bid | 1 | 2000 | ₹256,000 |
Reservation
Issue mix
QIB49.85%1,018,000 shares
Anchor Investor29.87%610,000 shares
QIB (Ex. Anchor)19.98%408,000 shares
NII (HNI)15.08%308,000 shares
bNII > ₹10L15.08%308,000 shares
Retail35.06%716,000 shares
Total100.00%2,042,000 shares
Company
Incorporated2010
Use of proceeds
| Object | Amount |
|---|---|
| Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities | ₹2.44 Cr |
| Capital Expenditure towards Construction of a Storage Facility | ₹3.62 Cr |
| Pre-payment/Repayment of outstanding Secured Loans | ₹1.86 Cr |
| Product Registrations in other countries | ₹2.69 Cr |
| Funding working capital requirements | ₹11.25 Cr |
| General Corporate Purposes | ₹2.85 Cr |
| Issue Expenses | ₹2.80 Cr |
| Total | ₹27.52 Cr |
Financial performance
Year-wise operating scale, profitability and balance-sheet context.Revenue19.51₹ Cr · -60.7% vs prior year
EBITDA4.24₹ Cr · -55.6% vs prior year
PAT2.87₹ Cr · -53.0% vs prior year
Assets56.29₹ Cr · +32.4% vs prior year
Net Worth19.10₹ Cr · +17.7% vs prior year
Borrowing15.32₹ Cr · -1.9% vs prior year
3-year financial trendRevenue / EBITDA / PAT
₹ crore31 Mar 2024
Assets33.88
Total Income35.87
EBITDA8.39
Profit After Tax4.87
NET Worth5.87
Reserves and Surplus5.37
Total Borrowing17.09
31 Mar 2025
Assets42.53
Total Income49.65
EBITDA9.54
Profit After Tax6.11
NET Worth16.23
Reserves and Surplus10.29
Total Borrowing15.62
31 Jul 2025
Assets56.29
Total Income19.51
EBITDA4.24
Profit After Tax2.87
NET Worth19.10
Reserves and Surplus13.16
Total Borrowing15.32
KPIs
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 55.25% |
| ROCE | 27.83% |
| Debt / Equity | 0.96% |
| RoNW | 37.62% |
| PAT Margin | 12.43% |
| EBITDA Margin | 19.41% |
| Price to Book Value | 12.64 |
Valuation & shareholding
Pre-IPO EPS10.29
Post-IPO EPS10.66
Pre-IPO P/E12.44
Post-IPO P/E12.01
Promoter holding pre92.68%
Promoter holding post68.03%
Market cap₹103.48 Cr.
Peer comparison
| Company | EPS | P/E | RoNW | NAV |
|---|---|---|---|---|
| Curis Lifesciences IPO | — | 12.01 x | — | — |
| Bio Medica IPO | — | 13.45 x | — | — |
| Goldline Pharmaceutical IPO | — | 14.56 x | — | — |
| Speciality Medicines IPO | — | 10.49 x | — | — |
Issue expenses
| Expense | Amount |
|---|---|
| Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities | ₹2.44 Cr |
| Capital Expenditure towards Construction of a Storage Facility | ₹3.62 Cr |
| Pre-payment/Repayment of outstanding Secured Loans | ₹1.86 Cr |
| Product Registrations in other countries | ₹2.69 Cr |
| Funding working capital requirements | ₹11.25 Cr |
| General Corporate Purposes | ₹2.85 Cr |
| Issue Expenses | ₹2.80 Cr |
| Total | ₹27.52 Cr |
Registrar & lead managers
Registrar
MUFG Intime India Pvt.Ltd.Lead managers
- Finaax Capital Advisors Pvt.Ltd.
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-09-10.
IPO UPDATE ALERTS
Register for IPO Updates →Track Curis Lifesciences without missing an update
Register for subscription, GMP, allotment and listing notifications.